TapImmune Inc. Appoints John Bonfiglio As Strategic Advisor
SEATTLE, Feb. 25, 2015 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor. John is a highly successful Biotech CEO with broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over $29 million dollars in the public markets while positioning the company for a successful re-listing on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million) and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation's Immunotherapy Division.
John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.
Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome John's appointment as a Strategic Advisor as we focus on improving the profile and shareholder value of the Company. We have been successful in progressing multiple technologies to the Phase II stage but need to do a much better job in conveying this success to the Capital Markets and increasing awareness so that the value we have built is translated into increased shareholder value. In this context John's expertise is particularly timely. As an advisor, John will work closely with myself to review our overall strategic direction and operations. This includes identification of new opportunities to obtain financing and development and implementation of an improved Capital Markets and Shareholders IR/PR program as well as counsel on drug development issues and strategy."
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative immunotherapy technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's product compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Glynn Wilson, Ph.D.
Chairman & CEO
Kirin M. Smith
Chief Operations Officer
Chief Communications Officer
J. Streicher Capital, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-appoints-john-bonfiglio-as-strategic-advisor-300041107.html
SOURCE TapImmune Inc.